Harbor Investment Advisory LLC Has $274,000 Stock Position in Boston Scientific Co. (NYSE:BSX)

Posted by Defense World Staff on Apr 3rd, 2023

Boston Scientific logo Harbor Investment Advisory LLC lowered its position in shares of Boston Scientific Co. (NYSE:BSX – Get Rating) by 15.0% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 5,931 shares of the medical equipment provider’s stock after selling 1,046 shares during the quarter. Harbor Investment Advisory LLC’s holdings in Boston Scientific were worth $274,000 at the end of the most recent quarter.

Other hedge funds have also made changes to their positions in the company. AdvisorNet Financial Inc raised its stake in Boston Scientific by 4.0% during the third quarter. AdvisorNet Financial Inc now owns 7,288 shares of the medical equipment provider’s stock worth $282,000 after acquiring an additional 282 shares in the last quarter. Gilbert & Cook Inc. boosted its holdings in shares of Boston Scientific by 2.6% during the 3rd quarter. Gilbert & Cook Inc. now owns 11,246 shares of the medical equipment provider’s stock worth $472,000 after buying an additional 289 shares in the last quarter. Parkside Financial Bank & Trust boosted its holdings in shares of Boston Scientific by 20.6% during the 1st quarter. Parkside Financial Bank & Trust now owns 1,793 shares of the medical equipment provider’s stock worth $79,000 after buying an additional 306 shares in the last quarter. CENTRAL TRUST Co boosted its holdings in shares of Boston Scientific by 3.6% during the 3rd quarter. CENTRAL TRUST Co now owns 8,862 shares of the medical equipment provider’s stock worth $343,000 after buying an additional 310 shares in the last quarter. Finally, SVB Wealth LLC boosted its holdings in shares of Boston Scientific by 3.1% during the 1st quarter. SVB Wealth LLC now owns 11,130 shares of the medical equipment provider’s stock worth $493,000 after buying an additional 336 shares in the last quarter. Institutional investors and hedge funds own 90.23% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts recently issued reports on BSX shares. StockNews.com started coverage on Boston Scientific in a report on Thursday, March 16th. They issued a “buy” rating on the stock. Truist Financial increased their price target on Boston Scientific from $50.00 to $54.00 and gave the company a “buy” rating in a research report on Tuesday, December 20th. Barclays increased their price target on Boston Scientific from $49.00 to $53.00 in a research report on Wednesday, January 4th. Morgan Stanley increased their price target on Boston Scientific from $50.00 to $56.00 and gave the company an “overweight” rating in a research report on Friday, January 6th. Finally, Stifel Nicolaus increased their price target on Boston Scientific from $50.00 to $52.00 in a research report on Wednesday, February 1st. One equities research analyst has rated the stock with a hold rating, fourteen have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Buy” and an average target price of $51.82.

Boston Scientific Trading Up 0.9 %

Shares of BSX opened at $50.03 on Monday. The business has a 50-day moving average of $47.42 and a 200 day moving average of $44.76. Boston Scientific Co. has a fifty-two week low of $34.98 and a fifty-two week high of $50.21. The firm has a market cap of $71.91 billion, a P/E ratio of 111.18, a price-to-earnings-growth ratio of 2.34 and a beta of 0.79. The company has a debt-to-equity ratio of 0.51, a quick ratio of 1.02 and a current ratio of 1.51.

Boston Scientific (NYSE:BSX – Get Rating) last announced its quarterly earnings data on Wednesday, February 1st. The medical equipment provider reported $0.45 earnings per share for the quarter, missing the consensus estimate of $0.47 by ($0.02). Boston Scientific had a return on equity of 14.29% and a net margin of 5.50%. The firm had revenue of $3.24 billion during the quarter, compared to analysts’ expectations of $3.24 billion. During the same period last year, the business posted $0.45 EPS. The company’s revenue was up 3.7% compared to the same quarter last year. As a group, research analysts forecast that Boston Scientific Co. will post 1.9 EPS for the current year.

Insider Buying and Selling

In other Boston Scientific news, EVP John Bradley Sorenson sold 4,000 shares of the firm’s stock in a transaction dated Friday, March 31st. The stock was sold at an average price of $50.00, for a total value of $200,000.00. Following the completion of the transaction, the executive vice president now owns 34,403 shares in the company, valued at approximately $1,720,150. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. In other Boston Scientific news, EVP John Bradley Sorenson sold 4,000 shares of the firm’s stock in a transaction dated Friday, March 31st. The stock was sold at an average price of $50.00, for a total value of $200,000.00. Following the completion of the transaction, the executive vice president now owns 34,403 shares in the company, valued at approximately $1,720,150. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CAO Jonathan Monson sold 5,000 shares of the firm’s stock in a transaction dated Wednesday, March 1st. The stock was sold at an average price of $46.66, for a total value of $233,300.00. Following the completion of the transaction, the chief accounting officer now owns 34,868 shares of the company’s stock, valued at approximately $1,626,940.88. The disclosure for this sale can be found here. In the last 90 days, insiders sold 130,885 shares of company stock valued at $6,204,217. 0.71% of the stock is owned by insiders.

Boston Scientific Profile

(Get Rating)

Boston Scientific Corp. engages in the development, manufacture and marketing of medical devices that are used in interventional medical procedures. It operates through the MedSurg and Cardiovascular segments. The MedSurg segment includes Urology and Neuromodulation. The Cardiovascular segment consists of Cardiology and Peripheral Interventions.